CRISPR Therapeutics AG (CRSP)

Overview News Price History Option Chain Why CRSP Down? Discussions Forecast

Why is CRISPR Therapeutics AG (CRSP) Stock down?

We've noticed a 5.29% decline in CRISPR Therapeutics AG (CRSP) stock during the 2024-04-10 trading session. While this could be attributed to normal volatility or various internal and external factors, please be aware that we are actively monitoring the situation, and we'll provide timely updates as soon as possible!

13 Nov, 2023:

CRISPR Therapeutics AG Stock (CRSP) dropped by 2.16% from $53.16 to $52.01 in the trading on Monday November 13, 2023. The reason why CRSP stock down today is due to the recent lower price target by the analysts.

On Monday, Morgan Stanley analyst Terence Flynn maintained CRISPR Therapeutics with an Underweight and lowered the price target from $43 to $42.
Last Tuesday, RBC Capital analyst Luca Issi maintains CRISPR Therapeutics with a Sector Perform and lowered the price target from $55 to $50.
Needham analyst Gil Blum maintained CRISPR Therapeutics with a Buy and lowered the price target from $88 to $85.

02 Oct, 2023:

CRISPR Therapeutics AG Stock (CRSP) dropped by 6.57% from $45.39 to 42.41 in the trading on Monday October 2, 2023. The reason why stock CRSP is down is due to upcoming FDA decisions for exa-cel. The company is awaiting FDA decisions on its exa-cel gene therapy for sickle cell disease and beta-thalassemia. These decisions are anticipated in the near future, and a few investors might be selling their CRSP shares before the decisions are made, which cause CRSP stock down.